Edgewise Therapeutics (EWTX) Financials

Edgewise Therapeutics (NASDAQ: EWTX) remains a classic clinical-stage biotech story: no revenue, meaningful operating losses, and a balance sheet that still looks well-funded. The latest quarter shows the company is continuing to spend heavily on R&D while relying on its large cash and investment portfolio to finance development.

Key takeaways from Q1 2026:

• The company ended Q1 2026 with $499.6 million in cash, cash equivalents, and short-term investments, which gives it a substantial runway for ongoing clinical development.
• Total current assets were $509.8 million versus only $22.5 million in current liabilities, indicating a very strong short-term liquidity position.
• Total liabilities were just $25.3 million, which is very low relative to $518.5 million in total assets.
• The company generated $2.4 million of net cash from investing activities in Q1 2026, helped by maturities/sales of investments exceeding new purchases.
• Cash and investments declined only modestly from $560.4 million at year-end 2025 to roughly $499.6 million at quarter-end, suggesting the balance sheet is still comfortably funded.
• Edgewise remains pre-revenue; total revenue was $0 in Q1 2026 and in each of the prior periods shown.
• The company continues to carry a large common stock balance and negative retained earnings, which is typical for a development-stage biotech that has funded operations through equity raises.
• Interest and investment income of $5.1 million helped offset losses, but investment income is not enough to cover operating expenses.
• Q1 2026 net loss was $49.9 million, compared with $50.0 million in Q4 2025 and $40.7 million in Q3 2025, so losses remain sizable.
• Operating cash burn was $42.5 million in Q1 2026, only slightly improved from $38.6 million in Q4 2025 and still well above zero.
• Research and development expense rose to $42.7 million in Q1 2026 from $43.6 million in Q4 2025, keeping the company in a high-spend mode as it advances its pipeline.
• Over the last four quarters, operating losses have consistently stayed in the $34 million to $56 million range, underscoring that profitability is still a long way off.

Trend analysis over the last several quarters:

Edgewise’s operating profile is relatively stable for a biotech at this stage: no product revenue, steady R&D-heavy spending, and recurring net losses. The good news is that the company is not under immediate funding pressure. Its cash and short-term investments have stayed above the $500 million mark for most of the period, and even after a down quarter in Q1 2026, the balance sheet still appears robust.

One notable trend is that investing gains from the company’s portfolio often cushion cash burn. In several quarters, sales and maturities of investments offset a large portion of operating losses. That does not change the underlying economics of the business, but it does help extend the runway.

Another important point for investors is that share count has risen materially over the last year, with weighted average shares increasing from roughly 95 million in Q1 2025 to more than 107 million in Q1 2026. That suggests ongoing dilution risk remains part of the story, even though the company is well capitalized today.

Bottom line: Edgewise Therapeutics has a strong cash position and little debt, which lowers near-term financial risk. However, it remains a pre-revenue biotech with substantial and persistent operating losses. For investors, the stock will likely continue to trade primarily on clinical progress rather than current financial performance.